|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| & IN MEMORY OF LAUREN KAYE...ASHLEY ANDERSON...TIM MAYHEW...MAKENZIE MOORE...COURTNEY MALEDON...NICKY MAILLIARD...SETH FELDMAN...MARK ERICKSON...DICK ARNOLD...(WE DO NOT ACCEPT ADVERTISING) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ThursdayModafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery
Modafinil appeared to be beneficial for improving wakefulness and responsiveness in a patient with central nervous system trauma in the post-operative state.MORE
WednesdayResults of a Survey of Neurosurgical Practice Patterns Regarding the Prophylactic use of Anti-Epilepsy Drugs in Patients with Brain TumorsMolecularly Targeted Therapy for Pediatric Brain TumorsConsiderations on the Role of Chemotherapy and Modern Radiotherapy in the Treatment of Childhood Low Grade GliomaThe treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspectivePhase I trial of temozolomide plus o6-benzylguanine for patients with recurrent or progressive malignant gliomaThe National Brain Tumor Foundation and the Brain Tumor Society are teaming up to provide a web conference on rehabilitation for brain tumor patients.
This conference arose out of the questions and concerns of the patients and family members we hear from on a daily basis.
The conference will be comprised of three, one hour, presentations. Presentations will run 45 minutes and will be followed by a ten minute question/answer exchange. All conferences will be held from 1:00-2:00 PM Eastern Daylight Time.
Individuals that are interested in attending can register by sending their name, mailing address and phone number to rehabconference@yahoo.com. Registration can also be completed by calling the National Brain Tumor Foundation at 800.934.2873 or the Brain Tumor Society at 800.770.8287. Dial-in instructions and details specific to each presentation will be provided after registration has been completed. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||